Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:affects |
Possible bone fractures
Possible kidney disease Possible stomach cancer risk increase Possible vitamin B12 deficiency |
| gptkbp:approves |
gptkb:European_Union
gptkb:United_States Short-term treatment of GERD Long-term treatment of Zollinger-Ellison syndrome |
| gptkbp:atccode |
A02 BC02
|
| gptkbp:available_on |
Generic drug
|
| gptkbp:brand |
gptkb:Protonix
|
| gptkbp:casnumber |
102625-71-8
|
| gptkbp:category |
Category B
|
| gptkbp:chemical_formula |
C16 H15 F2 N3 O3 S
|
| gptkbp:class |
Proton pump inhibitor
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
Severe liver disease
Hypersensitivity to pantoprazole |
| gptkbp:dosage_form |
gptkb:tablet
Injection 20 mg once daily 40 mg once daily |
| gptkbp:excretion |
Renal
|
| gptkbp:healthcare |
gptkb:2000
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pantoprazole
|
| gptkbp:interacts_with |
gptkb:Clopidogrel
gptkb:Methotrexate gptkb:Digoxin gptkb:Warfarin |
| gptkbp:lifespan |
1 hour
|
| gptkbp:mechanism_of_action |
Inhibits proton pump in gastric parietal cells
|
| gptkbp:metabolism |
Hepatic
|
| gptkbp:research_focus |
Cost-effectiveness analysis
Impact on gut microbiome Long-term safety in elderly patients Use in pediatric populations Comparative effectiveness with other PPIs |
| gptkbp:route_of_administration |
Intravenous
Oral |
| gptkbp:safety_features |
Generally well tolerated
|
| gptkbp:side_effect |
gptkb:Nausea
Diarrhea Dizziness Headache Abdominal pain |
| gptkbp:used_for |
gptkb:Zollinger-Ellison_syndrome
Gastroesophageal reflux disease (GERD) Erosive esophagitis |
| gptkbp:bfsParent |
gptkb:Lansoprazole
|
| gptkbp:bfsLayer |
6
|